Antibody binding epitope Mapping (AbMap) of two hundred antibodies in a single run

Huan Qi,Mingliang Ma,Chuansheng Hu,Zhao-wei Xu,Fan-lin Wu,Nan Wang,Dan-yun Lai,Yang Li,Shu-juan Guo,Xiaodong Zhao,Hua Li,Sheng-ce Tao
DOI: https://doi.org/10.1101/739342
IF: 7.381
2019-01-01
Molecular & Cellular Proteomics
Abstract:Epitope mapping is essential for the understanding how an antibody works. Given millions of antibodies short of epitope information, there is an urgent need for high-throughput epitope mapping. Here we combined a commercial phage displayed random peptide library of 109 diversity with next generation sequencing to develop Antibody binding epitope Mapping (AbMap) technology. Over two hundred antibodies were analyzed in a single test and epitopes were determined for >50% of them. Strikingly, the antibodies were able to recognize different proteins from multiple species with similar epitopes. We successfully identified the epitopes of 14 anti-PD-1 antibodies, including Sintilimab ( i.e. , L128, A129 and P130), and confirmed that the binding epitopes of Nivolumab and Sintilimab are very close to the binding interface of PD-1 and PD-L1. The predicted conformational epitopes of Pembrolizumab and Nivolumab are consistent with their antibody-antigen co-crystal structures. AbMap is the first technology enables high-throughput epitope mapping. Highlights
What problem does this paper attempt to address?